

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

**INSIDE INFORMATION  
UPDATE ON SHARE TRANSFER BY CONTROLLING  
SHAREHOLDER OF THE COMPANY**

**Financial Adviser to the Company**



This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 31 August 2021, 11 November 2021, 10 December 2021, 20 December 2021 and 30 December 2021 (the “**Announcements**”) in relation to the proposed transfer of 452,400,000 shares in the Company by Guangdong HEC Technology Holding Co., Ltd.\* (廣東東陽光科技控股股份有限公司) (the “**Parent Company**”), representing no more than 51.41% of the issued share capital of the Company (the “**Subject Assets**”), to Sunshine Lake Pharma Co., Ltd.\* (廣東東陽光藥業有限公司) (“**Sunshine Lake Pharma**”) and its wholly-owned subsidiary, HEC (Hong Kong) Sales Co., Limited (“**HEC (Hong Kong)**”). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has been informed by the Parent Company that, the remaining 111,901,200 H shares of the Company (equivalent to 12.72% of the issued share capital of the Company) held by the Parent Company have been transferred and registered under the name of HEC (Hong Kong). As at the date of this announcement, all the Subject Assets previously held by the Parent Company have been transferred to Sunshine Lake Pharma and HEC (Hong Kong).

On behalf of the Board  
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**TANG Xinfa**  
*Chairman*

Hubei, the PRC  
7 June 2022

*As at the date of this announcement, the board of directors of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.*

\* *For identification purposes only*